Bullish Views On Biotech But Political Issues Remain
There are a number of reasons why Henri Termeer, chairman and chief executive of Genzyme and chairman of the USA's Biotechnology Industry Organization, is bullish about the biotechnology industry, which he revealed in Ernst & Young's 10th Annual Biotechnology Industry report.
He believes that recognition of major breakthroughs within the industry is growing, and that large pharmaceutical companies want to make deals with biotechnology companies. He said combining strengths significantly improves efficiency, reduces duplication, and creates marvellous opportunities to increase the return to investors, and that as this happens, new investors will appear.
The political environment is another key issue that affects the industry. Mr Termeer illustrated this through the five major issues on the BIO's political agenda, and which are also the organization's goals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze